The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) late Friday announced it has granted a conditional marketing authorization for the Aucatzyl (obecabtagene autoleucel), a chimeric antigen receptor (CAR) T-cell therapy, to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
The new conditional marketing authorization was granted to UK-based Autolus Therapeutics (Nasdaq: AUTL).
“Continuing our momentum, this MHRA license is a significant milestone for Autolus as a company. With our scientific expertise, operations and manufacturing based in the UK, this is an important achievement for our company,” said Dr Christian Itin, chief executive of Autolus, adding: “We want to thank all the patients and investigators at the UK trial centers for their contributions towards this license, as well as the foundational work by our partners at UCL and our internal team.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze